AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10775890 — intervention group
Group type: COMPARATOR
Intervention: TRY+ (normal tryptophan diet with amino acid mixture with tryptophan)
Number of subjects: 30
Study 8803517 — intervention group
Group type: EXPERIMENTAL
Intervention: FK-224 (2 mg)
Number of subjects: 13
Study 8803517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8803517 — intervention group
Group type: COMPARATOR
Intervention: Saline plus ethanol (diluent for BK)
Number of subjects: 13
Study 1611544 — intervention group
Group type: EXPERIMENTAL
Intervention: tyrosine-adsorbed Dermatophagoides pteronyssinus vaccine
Number of subjects: 24
Study 1611544 — intervention group
Group type: EXPERIMENTAL
Intervention: prolonged hyposensitization
Number of subjects: 24
Study 1611544 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 6361299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine resin
Number of subjects: 3806
Study 6361299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3806
Study 31422722 — intervention group
Group type: EXPERIMENTAL
Intervention: Support-training system of peer group, 8 training sessions over 4 months
Number of subjects: 112
Study 31422722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study 29258367 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 6 months
Number of subjects: 200
Study 29258367 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 200
Study 25130052 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone (10, 20, and 40 mg)
Number of subjects: 9
Study 25130052 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone (40 mg)
Number of subjects: 9
Study 25130052 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (10, 20, and 40 mg)
Number of subjects: 9
Study 25130052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 24800725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 20 mg/month
Number of subjects: 35
Study 24800725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 40 mg/month
Number of subjects: 35
Study 24800725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg/month
Number of subjects: 35
Study 24800725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR (all doses)
Number of subjects: 35
Study 22177176 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (Group 1)
Number of subjects: 24
Study 22177176 — intervention group
Group type: COMPARATOR
Intervention: No training (Group 2)
Number of subjects: 24
Study 20037150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 120
Study 20037150 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 120
Study 20037150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with BMI >=30 kg/m²
Number of subjects: 120
Study 20037150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane MAC-hour
Number of subjects: 120
Study 20037150 — intervention group
Group type: COMPARATOR
Intervention: Desflurane MAC-hour
Number of subjects: 120
Study 26606967 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 and anti-CTLA-4/PD-1
Number of subjects: 0
Study 26606967 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion of regulatory T cells
Number of subjects: 0
Study 12752916 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 35
Study 12752916 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 35
Study 10699346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa OMPs vaccine
Number of subjects: 0
Study 10699346 — intervention group
Group type: COMPARATOR
Intervention: Post-immune sera of burn patients
Number of subjects: 0
Study 9356538 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.7 g/kg)
Number of subjects: 16
Study 9356538 — intervention group
Group type: COMPARATOR
Intervention: Medium-protein diet (1.0 g/kg)
Number of subjects: 16
Study 9356538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (2.1 g/kg)
Number of subjects: 16
Study 8403156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 25 micrograms
Number of subjects: 50
Study 8403156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 50 micrograms
Number of subjects: 50
Study 3780124 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 and 0.30 mg/kg)
Number of subjects: 12
Study 3780124 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg)
Number of subjects: 12
Study 3780124 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone + Diazepam (0.30 mg/kg)
Number of subjects: 12
Study 3780124 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.30 mg/kg)
Number of subjects: 12
Study 30074996 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-tailored multifactorial intervention
Number of subjects: 268
Study 30074996 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 268
Study 26815250 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise of the glenohumeral external rotators
Number of subjects: 0
Study 26815250 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional stress task (watching 'unpleasant' images)
Number of subjects: 0
Study 26815250 — intervention group
Group type: COMPARATOR
Intervention: Physical testing procedure
Number of subjects: 0
Study 25266547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg IM in the deltoid
Number of subjects: 46
Study 25266547 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole lauroxil 441 mg IM in the gluteal
Number of subjects: 46
Study 25266547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg IM in the deltoid or gluteal
Number of subjects: 46
Study 22382362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 or 10 mg/kg every 3 weeks for four doses followed by maintenance dosing
Number of subjects: 82
Study 22382362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 82
Study 20067654 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical or catheter interventional treatment of coarctation
Number of subjects: 14
Study 20067654 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 14
Study 18837100 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear liquid diet and overnight fast
Number of subjects: 0
Study 18837100 — intervention group
Group type: EXPERIMENTAL
Intervention: Purgative preparation
Number of subjects: 0
Study 16428147 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicic acid applied twice daily for 8 weeks
Number of subjects: 40
Study 16428147 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 8 weeks
Number of subjects: 40
Study 12588272 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted community booster seat campaign
Number of subjects: 3609
Study 12588272 — intervention group
Group type: COMPARATOR
Intervention: Control communities (no intervention)
Number of subjects: 3609
Study 10229307 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening based on maternal risk factors
Number of subjects: 84
Study 10229307 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g oral glucose tolerance test (OGTT)
Number of subjects: 84
Study 10229307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diabetic antenatal clinic
Number of subjects: 84
Study 10229307 — intervention group
Group type: EXPERIMENTAL
Intervention: Written guidelines for screening
Number of subjects: 84
Study 10229307 — intervention group
Group type: EXPERIMENTAL
Intervention: National guidelines for screening
Number of subjects: 84
Study 8902442 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/day E2 cream continuously for 12 months
Number of subjects: 40
Study 8902442 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 40
Study 1906893 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol administration
Number of subjects: 5
Study 1906893 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol administration
Number of subjects: 5
Study 1906893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (oral and transdermal)
Number of subjects: 5
Study 6347315 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy with graded pyloric dilatation (TV + PD)
Number of subjects: 41
Study 6347315 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy with pyloroplasty (TV + P)
Number of subjects: 41
Study 29335827 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐SES (ultrathin strut biodegradable polymer sirolimus‐eluting stent)
Number of subjects: 4
Study 28225648 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous human Schwann cell transplantation
Number of subjects: 6
Study 26200798 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Control Course (TCC)
Number of subjects: 109
Study 26200798 — intervention group
Group type: COMPARATOR
Intervention: Control group (individual low-intensity interventions)
Number of subjects: 109
Study 24714004 — intervention group
Group type: COMPARATOR
Intervention: 25 μg vaginal misoprostol
Number of subjects: 128
Study 24714004 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg vaginal misoprostol
Number of subjects: 128
Study 21971406 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat/high glycemic index (HIGH) diet with high-intensity physical activity (hi-PA)
Number of subjects: 41
Study 21971406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low saturated fat/low glycemic index (LOW) diet with high-intensity physical activity (hi-PA)
Number of subjects: 41
Study 19563429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials with stratified, blocked, or paired clusters before randomization (23 trials)
Number of subjects: 35
Study 19563429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials that adjusted for confounding in analysis (17 trials)
Number of subjects: 35
Study 19563429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials that did not account for clustering in sample size calculations (10 trials)
Number of subjects: 35
Study 19563429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials that did not account for the cluster-randomized design in analysis (7 trials)
Number of subjects: 35
Study 17702878 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 87
Study 17702878 — intervention group
Group type: COMPARATOR
Intervention: Weight Stable (WS)
Number of subjects: 87
Study 14770064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to enhance collaborative communication among nurse and physician leaders over 8 months
Number of subjects: 2
Study 11575229 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg + Hydrochlorothiazide 12.5 mg (V+H)
Number of subjects: 138
Study 11575229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 8988832 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 1 mg.kg-1
Number of subjects: 90
Study 8988832 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.5 mg.kg-1
Number of subjects: 90
Study 8988832 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study 8098251 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.5-F ureteroscopes used in the first 100 patients
Number of subjects: 400
Study 8098251 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturised ureteroscope used in the third group of 200 patients
Number of subjects: 400
Study 8098251 — intervention group
Group type: COMPARATOR
Intervention: Rigid ureteroscopes used in the second group of 100 patients
Number of subjects: 400
Study 8098251 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturised endoscopes used in the second series (1989-1990)
Number of subjects: 400
Study 2891316 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levocabastine (ocular)
Number of subjects: 66
Study 2891316 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levocabastine (nasal)
Number of subjects: 66
Study 2891316 — intervention group
Group type: COMPARATOR
Intervention: Flunisolide (nasal)
Number of subjects: 66
Study 2891316 — intervention group
Group type: COMPARATOR
Intervention: Naphazoline/antazoline (ocular)
Number of subjects: 66
Study 2891316 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levocabastine (nasal and ocular)
Number of subjects: 66
Study 30236511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg orally daily for 24 weeks)
Number of subjects: 31
Study 26966279 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 100 mg/d
Number of subjects: 29
Study 26966279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 29
Study 25543418 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 'Siguan' combined with Gallbladder Meridian acupoints
Number of subjects: 87
Study 25543418 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at Gallbladder Meridian acupoints
Number of subjects: 87
Study 22820064 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (5-min treadmill exercise and 20-min virtual-reality based activity, 3 times a week for 6 weeks)
Number of subjects: 92
Study 22820064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 92
Study 19781889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-help program (CBS)
Number of subjects: 73
Study 19781889 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized structured writing intervention (SWI)
Number of subjects: 73
Study 19781889 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 73
Study 18508801 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilia and inv(16) present
Number of subjects: 400
Study 18508801 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilia only or inv(16) only
Number of subjects: 400
Study 18508801 — intervention group
Group type: COMPARATOR
Intervention: Neither eosinophilia nor inv(16)
Number of subjects: 400
Study 18508801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both eosinophilia and inv(16)
Number of subjects: 400
Study 15967762 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention strategy aimed at assessment and modification of psychosocial prognostic factors
Number of subjects: 314
Study 15967762 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study 12628627 — intervention group
Group type: EXPERIMENTAL
Intervention: Elated-mood induction
Number of subjects: 0
Study 12628627 — intervention group
Group type: COMPARATOR
Intervention: Depressed-mood induction
Number of subjects: 0
Study 12628627 — intervention group
Group type: EXPERIMENTAL
Intervention: State happiness and positive coping responses
Number of subjects: 0
Study 12833113 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine for 14 days
Number of subjects: 36
Study 12833113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 months open treatment with 15 mg sibutramine and dietary advice
Number of subjects: 36
Study 12833113 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 36
Study 9798779 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative intraperitoneal chemotherapy (EPIC) with mitomycin C on postoperative day 1 and 5-fluorouracil on postoperative days 2 to 5
Number of subjects: 248
Study 9798779 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 248
Study 7900522 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 64
Study 7900522 — intervention group
Group type: COMPARATOR
Intervention: No magnesium sulfate (Control group)
Number of subjects: 64
Study 2612537 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran
Number of subjects: 12
Study 2612537 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 335989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus methylprednisolone
Number of subjects: 0
Study 335989 — intervention group
Group type: COMPARATOR
Intervention: Dextrose in water (control)
Number of subjects: 0
Study 31889973 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation meditation audio recording during breastfeeding
Number of subjects: 0
Study 31889973 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study 28119434 — intervention group
Group type: EXPERIMENTAL
Intervention: Early group (intravenous edaravone [30 mg] started before or during tPA)
Number of subjects: 165
Study 28119434 — intervention group
Group type: COMPARATOR
Intervention: Late group (edaravone started after tPA)
Number of subjects: 165
Study 25955191 — intervention group
Group type: COMPARATOR
Intervention: 400 IU of vitamin D
Number of subjects: 98
Study 25955191 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 IU of vitamin D
Number of subjects: 98
Study 23509106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 16
Study 23509106 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic meals differing in fat and carbohydrate content
Number of subjects: 16
Study 22321227 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 270
Study 22321227 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 270
Study 22321227 — intervention group
Group type: COMPARATOR
Intervention: High hs-CRP group (hs-CRP ≥ 3 mg/L)
Number of subjects: 270
Study 22321227 — intervention group
Group type: COMPARATOR
Intervention: Moderate hs-CRP group (hs-CRP 1-3 mg/L)
Number of subjects: 270
Study 22321227 — intervention group
Group type: COMPARATOR
Intervention: Normal hs-CRP group (hs-CRP < 1 mg/L)
Number of subjects: 270
Study 22321227 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (20 mg)
Number of subjects: 270
Study 22321227 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (40 mg)
Number of subjects: 270
Study 22321227 — intervention group
Group type: COMPARATOR
Intervention: High levels of preprocedural hs-CRP
Number of subjects: 270
Study 22321227 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 270
Study 22321227 — intervention group
Group type: COMPARATOR
Intervention: Advanced age
Number of subjects: 270
Study 22321227 — intervention group
Group type: COMPARATOR
Intervention: Renal failure
Number of subjects: 270
Study 19382480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongbian Navel Paste (TBP)
Number of subjects: 68
Study 19382480 — intervention group
Group type: COMPARATOR
Intervention: Maren Zipi pill (Control)
Number of subjects: 68
Study 16675486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 1739
Study 16675486 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 1739
Study 15569779 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 310
Study 15569779 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 310
Study 11412155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 0.12 mg.kg‐1
Number of subjects: 40
Study 11412155 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 40
Study 9297191 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazone oxidation
Number of subjects: 0
Study 9297191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadimidine acetylation
Number of subjects: 0
Study 8510001 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (3.0 mg)
Number of subjects: 4
Study 3543247 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) recombinant interferon (IFN) alfa‐2b at a dosage of 2 X 10(6) IU/m2 three times weekly.
Number of subjects: 97
Study 3543247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) recombinant interferon (IFN) alfa‐2b at a dosage of 30 X 10(6) IU/m2 for five consecutive days every 3 weeks.
Number of subjects: 97
Study 3543247 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of patients with prior nephrectomy, no prior treatment, and lack of bone metastases.
Number of subjects: 97
Study 3543247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SC and IV routes of administration.
Number of subjects: 97
Study 31033341 — intervention group
Group type: EXPERIMENTAL
Intervention: RISE program (5-day, 5 hours per day of yoga, meditation, lectures, and experiential activities)
Number of subjects: 121
Study 27160157 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg
Number of subjects: 90
Study 27160157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil de-escalation
Number of subjects: 90
Study 25403606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored stage-matched intervention (SMI)
Number of subjects: 533
Study 25403606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontailored health education intervention (HEI)
Number of subjects: 533
Study 25403606 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 533
Study 24114306 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score group
Number of subjects: 1760
Study 24114306 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen test group
Number of subjects: 1760
Study 24114306 — intervention group
Group type: COMPARATOR
Intervention: Delayed antibiotics group
Number of subjects: 1760
Study 22097104 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness Music Therapy
Number of subjects: 133
Study 22097104 — intervention group
Group type: COMPARATOR
Intervention: No Music Assertiveness
Number of subjects: 133
Study 22097104 — intervention group
Group type: COMPARATOR
Intervention: Music No Assertiveness
Number of subjects: 133
Study 19280097 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss plus Aerobic Exercise (WL + AEX)
Number of subjects: 86
Study 19280097 — intervention group
Group type: COMPARATOR
Intervention: Weight Loss (WL)
Number of subjects: 86